> No clinical efficacy, safety, pharmacology, non-clinical or manufacturing issues were raised and noadditional clinical studies are required by FDA to support NDA approval
Pretty happy with that all things considered.
- Forums
- ASX - By Stock
- BOT
- Ann: FDA Letter Requires Patient Instruction Update
Ann: FDA Letter Requires Patient Instruction Update, page-15
-
- There are more pages in this discussion • 281 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
(20min delay)
|
|||||
Last
36.5¢ |
Change
-0.010(2.67%) |
Mkt cap ! $669.7M |
Open | High | Low | Value | Volume |
38.0¢ | 38.0¢ | 36.5¢ | $736.5K | 1.980M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
18 | 557533 | 36.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.0¢ | 291573 | 13 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
17 | 590104 | 0.365 |
20 | 672492 | 0.360 |
19 | 654325 | 0.355 |
30 | 628600 | 0.350 |
15 | 1827759 | 0.345 |
Price($) | Vol. | No. |
---|---|---|
0.370 | 332916 | 14 |
0.375 | 384503 | 6 |
0.380 | 477378 | 11 |
0.385 | 842311 | 12 |
0.390 | 563938 | 4 |
Last trade - 11.58am 30/07/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online